Caplin Point Laboratories Ltd.
Caplin Point Laboratories Ltd. Fundamental Analysis
Caplin Point Laboratories Ltd. (CAPLIPOINT.BO) shows moderate financial fundamentals with a PE ratio of 44.62, profit margin of 29.11%, and ROE of 10.30%. The company generates $10.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze CAPLIPOINT.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakCAPLIPOINT.BO struggles to generate sufficient returns from assets.
Valuation Score
WeakCAPLIPOINT.BO trades at a premium to fair value.
Growth Score
ModerateCAPLIPOINT.BO shows steady but slowing expansion.
Financial Health Score
ModerateCAPLIPOINT.BO shows balanced financial health with some risks.
Profitability Score
WeakCAPLIPOINT.BO struggles to sustain strong margins.
Key Financial Metrics
Is CAPLIPOINT.BO Expensive or Cheap?
P/E Ratio
CAPLIPOINT.BO trades at 44.62 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CAPLIPOINT.BO's PEG of 3.23 indicates potential overvaluation.
Price to Book
The market values Caplin Point Laboratories Ltd. at 4.57 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 37.47 times EBITDA. This signals the market has high growth expectations.
How Well Does CAPLIPOINT.BO Make Money?
Net Profit Margin
For every $100 in sales, Caplin Point Laboratories Ltd. keeps $29.11 as profit after all expenses.
Operating Margin
Core operations generate 45.34 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.30 in profit for every $100 of shareholder equity.
ROA
Caplin Point Laboratories Ltd. generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Caplin Point Laboratories Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Caplin Point Laboratories Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
CAPLIPOINT.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
44.62
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.57
vs 25 benchmark
P/S Ratio
Price to sales ratio
12.94
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How CAPLIPOINT.BO Stacks Against Its Sector Peers
| Metric | CAPLIPOINT.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 44.62 | 29.45 | Worse (Expensive) |
| ROE | 10.30% | 779.00% | Weak |
| Net Margin | 29.11% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 4.65 | Weak Liquidity |
| ROA | 0.00% | -19344.00% (disorted) | Weak |
CAPLIPOINT.BO outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Caplin Point Laboratories Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation